- Home
- ACOG vs CGTX Comparison
ACOG vs CGTX Comparison
Compare ACOG & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACOG
- CGTX
- Stock Information
- Founded
- ACOG 2000
- CGTX 2007
- Country
- ACOG Canada
- CGTX United States
- Employees
- ACOG N/A
- CGTX N/A
- Industry
- ACOG
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACOG
- CGTX Health Care
- Exchange
- ACOG Nasdaq
- CGTX Nasdaq
- Market Cap
- ACOG 149.0M
- CGTX 158.8M
- IPO Year
- ACOG N/A
- CGTX 2021
- Fundamental
- Price
- ACOG $6.50
- CGTX $1.57
- Analyst Decision
- ACOG Strong Buy
- CGTX Strong Buy
- Analyst Count
- ACOG 1
- CGTX 3
- Target Price
- ACOG $18.00
- CGTX $2.83
- AVG Volume (30 Days)
- ACOG 90.6K
- CGTX 1.8M
- Earning Date
- ACOG 11-14-2025
- CGTX 11-07-2025
- Dividend Yield
- ACOG N/A
- CGTX N/A
- EPS Growth
- ACOG N/A
- CGTX N/A
- EPS
- ACOG N/A
- CGTX N/A
- Revenue
- ACOG $4,586,341.00
- CGTX N/A
- Revenue This Year
- ACOG N/A
- CGTX N/A
- Revenue Next Year
- ACOG $101.16
- CGTX N/A
- P/E Ratio
- ACOG N/A
- CGTX N/A
- Revenue Growth
- ACOG N/A
- CGTX N/A
- 52 Week Low
- ACOG $3.75
- CGTX $0.22
- 52 Week High
- ACOG $11.54
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- ACOG 35.21
- CGTX 44.00
- Support Level
- ACOG $6.55
- CGTX $1.53
- Resistance Level
- ACOG $6.95
- CGTX $1.78
- Average True Range (ATR)
- ACOG 0.41
- CGTX 0.13
- MACD
- ACOG -0.00
- CGTX -0.03
- Stochastic Oscillator
- ACOG 0.00
- CGTX 4.26
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.